Clinical Trials | March 23, 2024
AstraZeneca’s FLAURA2 Phase III trial showed favourable trend in EGFR-mutated advanced lung cancer
Combination shows consistent benefit across prespecified post-progression outcomes
Combination shows consistent benefit across prespecified post-progression outcomes
To accelerate the development of next-generation radioconjugates to treat cancer
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
The validations confirm the completion of the applications and commence the scientific review process
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
The product is expected to be launched in December 2023
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
Subscribe To Our Newsletter & Stay Updated
